"The Reason Behind Chemours Stock's 37% Morning Crash"

Chemours stock plummeted 37.3% after announcing a delay in releasing its Q4 and full-year financial results for 2023, along with the replacement of its CEO, CFO, and controller. Preliminary estimates indicate a 12% sales decline and a shift from profit to loss in 2023. The company cited potential material weaknesses in its internal financial reporting and mentioned reports to its ethics hotline. With a likely loss of $225-235 million, the stock's future remains uncertain, leading to a very bad news day for Chemours.